+++
title = "Figure S7"
date = "2019-01-24"
author = "Lukasz Migas"
cover = ""
description = "Figure S7 - CCSD plots for intact, endoS2 treated and deglycosylated IgG1 mAbs"
+++

## Figure caption

<sup>DT</sup>CCSD<sub>He</sub> plots for fully glycosylated (intact), partially deglycosylated (endo S2 treated) and fully deglycosylated (PNGase F treated) IgG1 mAbs (charge state range 22+ to 25+). Data fitted with Gaussians (cumulative fit plotted) and normalised against (IMS area fraction) x (MS peak height fraction). Width of shading around each peak denotes the standard deviation calculated, n=3.

[Open in another tab](https://upton-herceptin-2019.netlify.com/assets/Figure_S5.html)

## Interactive figure

<iframe
    width="1000"
    frameborder="0"
    height="1150"
    src="https://upton-herceptin-2019.netlify.com/assets/Figure_S5.html"
    style="background: #FFFFFF;"
></iframe>

## Reference

[Upton R, Migas LG, Pacholarz KJ, Beniston RG, Estdale S, Firth D, Barran PE.Hybrid mass spectrometry methods reveal lot-to-lot differences and delineate the effects of glycosylation on the tertiary structure of HerceptinÂ®. Chem. Sci. Advance Article (2019).](https://pubs.rsc.org/en/content/articlepdf/2019/sc/c8sc05029e)